| 1. Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ.. (2004) Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]., 47 (6): [PMID:14998329] [10.1021/jm030311v] |
| 2. Schmidhammer H, Daurer D, Wieser M, Monory K, Borsodi A, Elliott J, Traynor JR. (1997) Synthesis and biological evaluation of 14-alkoxymorphinans. 14.1 14-ethoxy-5-methyl substituted indolomorphinans with opioid receptor selectivity, 7 (2): [10.1016/S0960-894X(96)00599-9] |
| 3. Grundt P, Jales AR, Traynor JR, Lewis JW, Husbands SM.. (2003) 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles., 46 (8): [PMID:12672258] [10.1021/jm021073r] |
| 4. Archer S, Seyed-Mozaffari A, Jiang Q, Bidlack JM.. (1994) 14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties., 37 (11): [PMID:7515442] [10.1021/jm00037a008] |
| 5. Coop A, Rothman RB, Dersch C, Partilla J, Porreca F, Davis P, Jacobson AE, Rice KC.. (1999) delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole., 42 (9): [PMID:10229636] [10.1021/jm9807003] |
| 6. Portoghese PS, Sultana M, Takemori AE.. (1990) Design of peptidomimetic delta opioid receptor antagonists using the message-address concept., 33 (6): [PMID:2160538] [10.1021/jm00168a028] |
| 7. Portoghese PS, Sultana M, Takemori AE.. (1990) Design of peptidomimetic delta opioid receptor antagonists using the message-address concept., 33 (6): [PMID:2160538] [10.1021/jm00168a028] |
| 8. Portoghese PS, Nagase H, MaloneyHuss KE, Lin CE, Takemori AE.. (1991) Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole., 34 (5): [PMID:1851846] [10.1021/jm00109a027] |
| 9. Portoghese PS.. (1991) An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists., 34 (6): [PMID:1648136] [10.1021/jm00110a001] |
| 10. Olmsted SL, Takemori AE, Portoghese PS.. (1993) A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists., 36 (1): [PMID:8380614] [10.1021/jm00053a025] |
| 11. Korlipara VL, Takemori AE, Portoghese PS.. (1994) N-benzylnaltrindoles as long-acting delta-opioid receptor antagonists., 37 (12): [PMID:8021928] [10.1021/jm00038a018] |
| 12. Portoghese PS, Ohkawa S, Moe ST, Takemori AE.. (1994) Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety., 37 (12): [PMID:8021929] [10.1021/jm00038a019] |
| 13. Farouz-Grant F, Portoghese PS.. (1997) Pyrrolomorphinans as delta opioid receptor antagonists. The role of steric hindrance in conferring selectivity., 40 (13): [PMID:9207938] [10.1021/jm970189y] |
| 14. Coop A, Jacobson AE, Aceto MD, Harris LS, Traynor JR, Woods JH, Rice KC.. (2000) N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole., 10 (21): [PMID:11078198] [10.1016/s0960-894x(00)00479-0] |
| 15. Kshirsagar TA, Fang X, Portoghese PS.. (1998) 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors., 41 (14): [PMID:9651172] [10.1021/jm980209b] |
| 16. Portoghese PS, Sultana M, Nagase H, Takemori AE.. (1988) Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists., 31 (2): [PMID:2828619] [10.1021/jm00397a001] |
| 17. Carroll FI, Zhang L, Mascarella SW, Navarro HA, Rothman RB, Cantrell BE, Zimmerman DM, Thomas JB.. (2004) Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity., 47 (2): [PMID:14711299] [10.1021/jm030419a] |
| 18. Ananthan S, Johnson CA, Carter RL, Clayton SD, Rice KC, Xu H, Davis P, Porreca F, Rothman RB.. (1998) Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety., 41 (15): [PMID:9667975] [10.1021/jm980083i] |
| 19. Ullrich T, Dersch CM, Rothman RB, Jacobson AE, Rice KC.. (2001) Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor., 11 (21): [PMID:11597422] [10.1016/s0960-894x(01)00580-7] |
| 20. Gao P, Larson DL, Portoghese PS.. (1998) Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors., 41 (16): [PMID:9685249] [10.1021/jm9802214] |
| 21. Salvadori S, Balboni G, Guerrini R, Tomatis R, Bianchi C, Bryant SD, Cooper PS, Lazarus LH.. (1997) Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity., 40 (19): [PMID:9301674] [10.1021/jm9607663] |
| 22. Grundt P, Martinez-Bermejo F, Lewis JW, Husbands SM.. (2003) Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge., 46 (14): [PMID:12825957] [10.1021/jm030801n] |
| 23. Schiller PW, Weltrowska G, Nguyen TM, Wilkes BC, Chung NN, Lemieux C.. (1993) TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity., 36 (21): [PMID:8230106] [10.1021/jm00073a020] |
| 24. Dondio G, Ronzoni S, Eggleston DS, Artico M, Petrillo P, Petrone G, Visentin L, Farina C, Vecchietti V, Clarke GD.. (1997) Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept., 40 (20): [PMID:9379438] [10.1021/jm9608218] |
| 25. Coop A, Pinto J, Wang L, McCullough K, Rothman RB, Dersch C, Jacobson AE, Rice KC.. (1999) Delta opioid binding selectivity of 3-ether analogs of naltrindole., 9 (24): [PMID:10617086] [10.1016/s0960-894x(99)00622-8] |
| 26. Ananthan S, Kezar HS, Carter RL, Saini SK, Rice KC, Wells JL, Davis P, Xu H, Dersch CM, Bilsky EJ, Porreca F, Rothman RB.. (1999) Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans., 42 (18): [PMID:10479286] [10.1021/jm990039i] |
| 27. Anzini M, Canullo L, Braile C, Cappelli A, Gallelli A, Vomero S, Menziani MC, De Benedetti PG, Rizzo M, Collina S, Azzolina O, Sbacchi M, Ghelardini C, Galeotti N.. (2003) Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity., 46 (18): [PMID:12930147] [10.1021/jm0307640] |
| 28. Sasaki Y, Chiba T.. (1995) Novel deltorphin heptapeptide analogs with potent delta agonist, delta antagonist, or mixed mu antagonist/delta agonist properties., 38 (20): [PMID:7562933] [10.1021/jm00020a013] |
| 29. Portoghese PS, Farouz-Grant F, Sultana M, Takemori AE.. (1995) 7'-Substituted amino acid conjugates of naltrindole. Hydrophilic groups as determinants of selective antagonism of delta 1 opioid receptor-mediated antinociception in mice., 38 (3): [PMID:7853332] [10.1021/jm00003a002] |
| 30. Portoghese PS, Larson DL, Sultana M, Takemori AE.. (1992) Opioid agonist and antagonist activities of morphindoles related to naltrindole., 35 (23): [PMID:1333013] [10.1021/jm00101a009] |
| 31. Klein P, Nelson WL.. (1992) O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay., 35 (24): [PMID:1335078] [10.1021/jm00102a012] |
| 32. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS.. (1998) Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors., 41 (25): [PMID:9836606] [10.1021/jm9805182] |
| 33. May EL, Jacobson AE, Mattson MV, Traynor JR, Woods JH, Harris LS, Bowman ER, Aceto MD.. (2000) Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues., 43 (26): [PMID:11150174] [10.1021/jm000317+] |
| 34. Ananthan S, Kezar HS, Saini SK, Khare NK, Davis P, Dersch CM, Porreca F, Rothman RB.. (2003) Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans., 13 (3): [PMID:12565965] [10.1016/s0960-894x(02)00934-4] |
| 35. Schütz J, Dersch CM, Horel R, Spetea M, Koch M, Meditz R, Greiner E, Rothman RB, Schmidhammer H.. (2002) Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans., 45 (24): [PMID:12431065] [10.1021/jm020940p] |
| 36. Srivastava SK, Husbands SM, Aceto MD, Miller CN, Traynor JR, Lewis JW.. (2002) 4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity., 45 (2): [PMID:11784158] [10.1021/jm010841w] |
| 37. Portoghese PS, Sultana M, Moe ST, Takemori AE.. (1994) Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety., 37 (5): [PMID:8126697] [10.1021/jm00031a006] |
| 38. Kubota H, Rothman RB, Dersch C, McCullough K, Pinto J, Rice KC.. (1998) Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives., 8 (7): [PMID:9871544] [10.1016/s0960-894x(98)00105-x] |
| 39. Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS.. (2001) Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus., 44 (6): [PMID:11300867] [10.1021/jm000381r] |
| 40. Clayson J, Jales A, Tyacke RJ, Hudson AL, Nutt DJ, Lewis JW, Husbands SM.. (2001) Selective delta-opioid receptor ligands: potential PET ligands based on naltrindole., 11 (7): [PMID:11294396] [10.1016/s0960-894x(01)00112-3] |
| 41. Grundt P, Williams IA, Lewis JW, Husbands SM.. (2004) Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore., 47 (21): [PMID:15456250] [10.1021/jm040807s] |
| 42. Peng Y, Keenan SM, Zhang Q, Kholodovych V, Welsh WJ.. (2005) 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies., 48 (5): [PMID:15743203] [10.1021/jm049117e] |
| 43. Li T, Fujita Y, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Salvadori S, Lazarus LH, Okada Y.. (2005) Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists., 48 (25): [PMID:16335927] [10.1021/jm050377l] |
| 44. Thomas JB, Zhang L, Navarro HA, Carroll FI.. (2006) Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor., 49 (18): [PMID:16942033] [10.1021/jm060459p] |
| 45. Fichna J, do-Rego JC, Chung NN, Lemieux C, Schiller PW, Poels J, Broeck JV, Costentin J, Janecka A.. (2007) Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2)., 50 (3): [PMID:17266203] [10.1021/jm060998u] |
| 46. Srivastava SK, Shefali S, Miller CN, Aceto MD, Traynor JR, Lewis JW, Husbands SM.. (2004) Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan., 47 (26): [PMID:15588100] [10.1021/jm040817t] |
| 47. Duval RA, Allmon RL, Lever JR.. (2007) Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors., 50 (9): [PMID:17402725] [10.1021/jm0700013] |
| 48. Arduin M, Spagnolo B, Calò G, Guerrini R, Carrà G, Fischetti C, Trapella C, Marzola E, McDonald J, Lambert DG, Regoli D, Salvadori S.. (2007) Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids., 15 (13): [PMID:17490886] [10.1016/j.bmc.2007.04.026] |
| 49. Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC.. (2007) Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series., 50 (16): [PMID:17625813] [10.1021/jm061325e] |
| 50. Bernard D, Coop A, MacKerell AD.. (2007) Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity., 50 (8): [PMID:17367120] [10.1021/jm0612463] |
| 51. Sakami S, Kawai K, Maeda M, Aoki T, Fujii H, Ohno H, Ito T, Saitoh A, Nakao K, Izumimoto N, Matsuura H, Endo T, Ueno S, Natsume K, Nagase H.. (2008) Design and synthesis of a metabolically stable and potent antitussive agent, a novel delta opioid receptor antagonist, TRK-851., 16 (17): [PMID:18701308] [10.1016/j.bmc.2008.07.065] |
| 52. Schneider HJ.. (2008) Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?, 43 (11): [PMID:18403056] [10.1016/j.ejmech.2008.02.011] |
| 53. Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS.. (2007) Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia., 104 (14): [PMID:17389363] [10.1073/pnas.0700295104] |
| 54. Sakami S, Maeda M, Kawai K, Aoki T, Kawamura K, Fujii H, Hasebe K, Nakajima M, Endo T, Ueno S, Ito T, Kamei J, Nagase H.. (2008) Structure-antitussive activity relationships of naltrindole derivatives. Identification of novel and potent antitussive agents., 51 (15): [PMID:18637671] [10.1021/jm701440h] |
| 55. Li G, Aschenbach LC, He H, Selley DE, Zhang Y.. (2009) 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies., 19 (6): [PMID:19217280] [10.1016/j.bmcl.2008.12.093] |
| 56. Kurimura M, Liu H, Sulima A, Hashimoto A, Przybyl AK, Ohshima E, Kodato S, Deschamps JR, Dersch CM, Rothman RB, Lee YS, Jacobson AE, Rice KC.. (2008) Probes for narcotic receptor mediated phenomena. 37. Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of the ortho- and para-d-isomers., 51 (24): [PMID:19053757] [10.1021/jm800913d] |
| 57. Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM.. (2009) Syntheses of novel high affinity ligands for opioid receptors., 19 (8): [PMID:19282177] [10.1016/j.bmcl.2009.02.078] |
| 58. Nagase H, Osa Y, Nemoto T, Fujii H, Imai M, Nakamura T, Kanemasa T, Kato A, Gouda H, Hirono S.. (2009) Design and synthesis of novel delta opioid receptor agonists and their pharmacologies., 19 (10): [PMID:19362480] [10.1016/j.bmcl.2009.03.099] |
| 59. Li F, Gaob L, Yin C, Chen J, Liu J, Xie X, Zhang A.. (2009) Synthesis and opioid receptor activity of indolopropellanes., 19 (16): [PMID:19595591] [10.1016/j.bmcl.2009.06.093] |
| 60. Purington LC, Pogozheva ID, Traynor JR, Mosberg HI.. (2009) Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties., 52 (23): [PMID:19788201] [10.1021/jm9007483] |
| 61. Ghirmai S, Azar MR, Cashman JR.. (2009) Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation., 17 (18): [PMID:19683449] [10.1016/j.bmc.2009.07.069] |
| 62. Fichna J, Lewellyn K, Yan F, Roth BL, Zjawiony JK.. (2011) Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids., 21 (1): [PMID:21115248] [10.1016/j.bmcl.2010.11.046] |
| 63. Majumdar S, Burgman M, Haselton N, Grinnell S, Ocampo J, Pasternak AR, Pasternak GW.. (2011) Generation of novel radiolabeled opiates through site-selective iodination., 21 (13): [PMID:21621410] [10.1016/j.bmcl.2011.05.008] |
| 64. Miyata Y, Fujii H, Osa Y, Kobayashi S, Takeuchi T, Nagase H.. (2011) Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi., 21 (16): [PMID:21764311] [10.1016/j.bmcl.2011.06.085] |
| 65. Tukey RH, Strassburg CP.. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease., 40 (1): [PMID:10836148] [10.1146/annurev.pharmtox.40.1.581] |
| 66. Ida Y, Nemoto T, Hirayama S, Fujii H, Osa Y, Imai M, Nakamura T, Kanemasa T, Kato A, Nagase H.. (2012) Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists., 20 (2): [PMID:22197670] [10.1016/j.bmc.2011.11.047] |
| 67. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ.. (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier., 294 (1): [PMID:10871297] |
| 68. Ida Y, Matsubara A, Nemoto T, Saito M, Hirayama S, Fujii H, Nagase H.. (2012) Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands., 20 (19): [PMID:22967810] [10.1016/j.bmc.2012.08.004] |
| 69. Polepally PR, White K, Vardy E, Roth BL, Ferreira D, Zjawiony JK.. (2013) Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands., 23 (10): [PMID:23587424] [10.1016/j.bmcl.2013.03.111] |
| 70. Germain AR, Carmody LC, Nag PP, Morgan B, Verplank L, Fernandez C, Donckele E, Feng Y, Perez JR, Dandapani S, Palmer M, Lander ES, Gupta PB, Schreiber SL, Munoz B.. (2013) Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells., 23 (6): [PMID:23403082] [10.1016/j.bmcl.2013.01.025] |
| 71. Zhang Y, Elbegdorj O, Yuan Y, Beletskaya IO, Selley DE.. (2013) Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives., 23 (13): [PMID:23721804] [10.1016/j.bmcl.2013.05.027] |
| 72. Zaidi SA, Arnatt CK, He H, Selley DE, Mosier PD, Kellogg GE, Zhang Y.. (2013) Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists., 21 (21): [PMID:24055076] [10.1016/j.bmc.2013.08.042] |
| 73. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 74. Perlikowska R, Piekielna J, Mazur M, Koralewski R, Olczak J, do Rego JC, Fichna J, Modranka J, Janecki T, Janecka A.. (2014) Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2., 22 (17): [PMID:25047937] [10.1016/j.bmc.2014.06.056] |
| 75. Polepally PR, Huben K, Vardy E, Setola V, Mosier PD, Roth BL, Zjawiony JK.. (2014) Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor., 85 [PMID:25193297] [10.1016/j.ejmech.2014.07.077] |
| 76. Kumar V, Clark MJ, Traynor JR, Lewis JW, Husbands SM.. (2014) Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists., 22 (15): [PMID:24973818] [10.1016/j.bmc.2014.05.065] |
| 77. Nemoto T, Iihara Y, Hirayama S, Iwai T, Higashi E, Fujii H, Nagase H.. (2015) Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists., 25 (15): [PMID:26048798] [10.1016/j.bmcl.2015.05.038] |
| 78. Kutsumura N, Nakajima R, Koyama Y, Miyata Y, Saitoh T, Yamamoto N, Iwata S, Fujii H, Nagase H.. (2015) Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound., 25 (21): [PMID:26099536] [10.1016/j.bmcl.2015.06.002] |
| 79. (2010) Compositions and methods for inhibiting g protein signaling, |
| 80. Kutsumura N, Koyama Y, Nagumo Y, Nakajima R, Miyata Y, Yamamoto N, Saitoh T, Yoshida N, Iwata S, Nagase H.. (2017) Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives., 25 (16): [PMID:28662966] [10.1016/j.bmc.2017.06.026] |
| 81. Ahonen TJ, Rinne M, Grutschreiber P, Mätlik K, Airavaara M, Schaarschmidt D, Lang H, Reiss D, Xhaard H, Gaveriaux-Ruff C, Yli-Kauhaluoma J, Moreira VM.. (2018) Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors., 151 [PMID:29649744] [10.1016/j.ejmech.2018.02.074] |
| 82. Zhang T, Han Z, Shi X, Zhao W, Wang Z, Zhang R, Xu B, Zhang M, Zhang Q, Xiao J, Zhu H, Zheng T, Fang Q.. (2019) Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation., 27 (4): [PMID:30626554] [10.1016/j.bmc.2019.01.003] |
| 83. Pasquinucci L, Turnaturi R, Calò G, Pappalardo F, Ferrari F, Russo G, Arena E, Montenegro L, Chiechio S, Prezzavento O, Parenti C.. (2019) (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist., 168 [PMID:30822708] [10.1016/j.ejmech.2019.02.043] |
| 84. Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, Hunkele A, Pagirsky J, Eans SO, Medina JM, Xu J, Pan YX, Borics A, Pasternak GW, McLaughlin JP, Majumdar S.. (2016) Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2., 59 (18): [PMID:27556704] [10.1021/acs.jmedchem.6b00748] |
| 85. Stefanucci A, Lei W, Pieretti S, Dimmito MP, Luisi G, Novellino E, Nowakowski M, Koźmiński W, Mirzaie S, Zengin G, Streicher JM, Mollica A.. (2019) Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis: in Vivo and in Vitro Biological Profile., 10 (4): [PMID:30996778] [10.1021/acsmedchemlett.8b00495] |
| 86. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 87. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 88. Pasquinucci L, Parenti C, Ruiz-Cantero MC, Georgoussi Z, Pallaki P, Cobos EJ, Amata E, Marrazzo A, Prezzavento O, Arena E, Dichiara M, Salerno L, Turnaturi R.. (2020) Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists., 11 (5): [PMID:32435370] [10.1021/acsmedchemlett.9b00549] |
| 89. Fujii H, Uchida Y, Shibasaki M, Nishida M, Yoshioka T, Kobayashi R, Honjo A, Itoh K, Yamada D, Hirayama S, Saitoh A.. (2020) Discovery of δ opioid receptor full agonists lacking a basic nitrogen atom and their antidepressant-like effects., 30 (12): [PMID:32299730] [10.1016/j.bmcl.2020.127176] |
| 90. Zampieri D, Fortuna S, Romano M, Amata E, Dichiara M, Marrazzo A, Pasquinucci L, Turnaturi R, Mamolo MG.. (2022) Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands., 72 [PMID:35724925] [10.1016/j.bmcl.2022.128860] |
| 91. Dichiara M, Artacho-Cordón A, Turnaturi R, Santos-Caballero M, González-Cano R, Pasquinucci L, Barbaraci C, Rodríguez-Gómez I, Gómez-Guzmán M, Marrazzo A, Cobos EJ, Amata E.. (2022) Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation., 230 [PMID:35016113] [10.1016/j.ejmech.2021.114091] |
